Helioson’s HP-001 will be presented at the 30th European Hematology Association (EHA) Congress on the poster session, June 14^th.

       The EHA Congress is one of the largest international conferences in the field of hematology, covering various aspects of hematology research. EHA is one of the largest independent providers of hematology knowledge globally and is the largest hematology organization in Europe. The 30th EHA Congress will be held in Milan, Italy from June 12th to June 15th in a hybrid format combining both online and on-site participation.

Abstract: PS1680

Title: HP-001, AN ORAL IKZF 1/3 MOLECULAR GLUE, DEMONSTRATED SUPERIOR DEGRADATION POTENCY AND SPECIFITY IN THE PRE-CLINICAL MODEL

Type: Poster Presentat

Session title: Myeloma and other monoclonal gammopathies - Biology & translational research

Link：

https://library.ehaweb.org/eha/2025/eha2025-congress/4160755/dihuang.wang.hp-001.an.oral.ikzf.1.3.molecular.glue.demonstrated.superior.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31568%2Amarker%3D5844

About Helioson

Shanghai Helioson Pharmaceutical Co., Ltd. was established in Oct. 2021, located in Pujiang Smart Plaza, Minhang District, Shanghai. The company is dedicated to developing innovative drugs with the focus on clinical value and in-depth insight into disease mechanisms. Relying on the cutting-edge technology platforms (Protein Steady-state and CADD) to drive the development of differentiated and globally-valuable drugs, Helioson’s pipeline comprises a growing number of molecular glue /PROTAC programs on oncology and auto-immune diseases.